[Christopher Robb]

A rather typical scenario much enjoyed by the dreaded Medical Monopoly. Now they have you and you go on paying as diagnosis NOT causes come spilling out in the interests of big pharma and the greed of the Medical Monopoly. 🥶

[gratitude]

Yes! Thanks HelenT for writing it so clearly. I have a friend in Canada who was sucked into the machine sooo easily. More than a handful of doctors and even more tests. And while I gently suggested caution, it was their own prompting to follow the system dictates. The reply was that in Canada it’s not financial incentives that prompt doctors to act so – unless maybe doctors get lots from the govt. there. I don’t know. Either way, I believe that many doctors do care and want to help their patients to heal, but it’s the system itself that hardly allows for that and obviously confronts and blunts that impulse.

[Gary Graziano]

I don’t doubt the underlying premise, that diagnosis can be a trap. I’ll relate an instance where it wasn’t. Around 15 years ago I started having a problem with one of my eyes. My vision would start jumping around. It was almost like double vision, but fluctuating. It was mostly just annoying, except it got serious if it occurred while driving. My wife finally got me to see an ophthalmologist, who couldn’t diagnose the problem. He recommended one of the pre-eminent neuro-ophthalmologists in the US. An office visit to this venerable gent was quite expensive, and not covered by insurance. He put me through an exhaustive battery of tests, and came to the conclusion I had Superior Oblique Myokymia… a twitch behind my left eye. It’s apparently rare enough that he was excited to see a case, and he invited a number of his colleagues to observe. I put the $64,000 question to him: what can we do about this? He said there were some anti-convulsant drugs he could prescribe, but their side-effects were worse than the condition. He suggested I take a period of 4 months or so to see if I could earn to live with it. We also discussed possible causes, and discovered the likely culprit. I had been involved in a head-on collision that totaled our car. A seatbelt broke my collarbone and the airbag knocked me out. That concussive injury was probably what caused it. Anyway, I took his advice. I discovered a couple of “work arounds,” and later discovered that a 15% DMSO in distilled water eye drop did well to calm things down during a flareup. I use it before a lengthy driving stint as a preventative, too. That may have been the last interaction with an MD which didn’t result in the treatment trap you describe.

[RobertKoch]

Helen:

The question in the title is the right one. The honest answer is both, depending on what produced the label.

Three lab tests do most of the trapping in modern infectious-disease diagnosis: the ELISA, the Western blot, and PCR. The industry says they detect proteins, antibodies, and viral genetic material respectively. None of them does what the industry says.

Take the Western blot, because it is the cleanest example.

One example is HIV: The industry tells the patient that the Western blot has revealed “antibodies to HIV proteins p24, p17, gp41, and gp120.” The patient hears the language of identification — that specific molecular entities, characteristic of a specific virus, have been found in his blood.

That is not what the laboratory has done.

The designation p24 does not name a particular protein. It names a band on a gel — a band whose migration distance corresponds to a molecular weight of approximately twenty-four kilodaltons. The lowercase p stands for “protein.” The number stands for the protein’s approximate mass in kilodaltons. Together they describe one physical property of an object: how heavy it is. That is the entire content of the measurement. The diagnosis “HIV-positive” is then attached to that weight, by convention, written into a lab manual. The band at the 24-kilodalton position is called HIV p24. The naming is the only thing tying that band to the alleged virus.

Imagine a police officer who tells the court he has identified a robbery suspect by weight alone. He places the suspect on a bathroom scale, reads 175 pounds, and announces: that is the man we want. The scale is calibrated. The reading is real. None of that is in dispute. What is in dispute is whether a single number on a scale can identify one human being in a city of millions, when tens of thousands of other men weigh exactly the same amount. No competent court would accept that identification. Weight is a property. It is not a fingerprint. It is not a face. It is not a name.

The HIV Western blot operates on the same logic, with the same defect. The gel separates proteins by molecular weight — one property, measured along one axis. A band appears at the twenty-four-kilodalton position. The test announces: that is HIV p24. But a 24-kilodalton band, like a 175-pound man, is a coordinate shared by an enormous number of unrelated candidates. The 24-kilodalton position is shared by human transaldolase, several histone variants, ribosomal L13a, and immunoglobulin light-chain fragments, among others. The 41-kilodalton position — gp41 in the test’s nomenclature — overlaps with actin, the most abundant protein in every human cell. The 66-kilodalton position overlaps with albumin, the most abundant protein in human serum.

The Western blot has no second property with which to distinguish a named “HIV band” from any of those confounders. No sequencing. No mass-spectrometric confirmation. No specificity control against a purified reference protein. No functional assay. The detective has identified the suspect by weight. The lab has identified the protein by mass. The structural error is the same.

And the interpretive rule that converts band positions into “positive” is jurisdictional. A Western blot reactive at p24, gp41, and gp120 meets the U.S. CDC criteria for “positive,” fails the Australian criteria of the same period, and falls into “indeterminate” under the WHO ruleset — simultaneously, on the same strip, with the same patient. The biology has not changed. What has changed is which institutional authority is reading the gel.

The ELISA, the screening test that sits upstream of the blot, has the same character. The industry says it detects antibodies to HIV. What it actually detects is reactivity between the patient’s serum and a mixture of proteins harvested from a cell-culture system that was used to grow what was alleged to be HIV. The mixture necessarily contains both viral proteins (if any) and cellular proteins from the host cell line, in proportions that vary by manufacturer and preparation. Reactivity at the relevant band positions has been documented in the peer-reviewed literature in patients with pregnancy, recent vaccination, autoimmune disease, tuberculosis, malaria, leprosy, multiple transfusions, liver disease, and recent organ transplantation. The reactivity is real. The bands appear. What the bands are is the question the test was never built to answer.

PCR is the third leg. The industry says it detects viral genetic material. What it actually does is amplify a selected genetic sequence — double whatever target is in the sample, every cycle. Thirty cycles produces about a billion-fold copy. Forty cycles, roughly a trillion-fold. Whatever was there originally — a fragment of replication-competent virus, a fragment of dead viral debris, a contaminant from a neighboring specimen, residual nucleic acid from a prior infection, a fragment of an endogenous retroviral sequence already present in the patient’s own genome, or laboratory background — comes out the other end looking like a positive result. The cycle threshold value, which would tell the clinician how faint the original signal was, is in standard practice not reported. The clinician sees POSITIVE.

Kary Mullis, who invented PCR and won the Nobel Prize for it, was explicit about what the method does and does not do:

“PCR is just a process that allows you to make a whole lot of something out of something. It doesn’t tell you that you are sick, and it doesn’t tell you that the thing you ended up with was really going to hurt you. With PCR, if you do it well, you can find almost anything in anybody.”

There is one diagnostic technique that does directly observe whether a virus is present in a patient’s specimen. Electron microscopy. It does not amplify, infer, or interpret. It photographs the particle, in the specimen, at known magnification, with measurable morphology. It is the technique by which poliovirus, influenza, hepatitis B, herpes simplex, measles, rabies, and vaccinia were characterized and confirmed as discrete viral entities. It is not part of any routine clinical HIV diagnostic protocol. Not at the CDC. Not at the College of American Pathologists. Not in the Clinical and Laboratory Standards Institute documents. Not in any manufacturer-recommended testing sequence. The one test that could resolve, by direct observation, the question the antibody and amplification tests pose indirectly — the dispositive observational technique of twentieth-century virology — is structurally absent from the workflow at every point.

That absence is the spell the original post is describing, viewed from the chemistry side. The label sticks because the test sounds authoritative (“PCR detected viral RNA,” “Western blot positive for HIV p24”). What was actually measured was a weight on a gel, a binding event between unidentified molecules, and the millionfold amplification of a fragment whose origin the technique cannot determine. The question the patient is never told to ask — show me the particle, in my blood, photographed at the magnification at which every other virus of the twentieth century was confirmed — is the question the diagnostic apparatus is built to never ask.

I wrote about one downstream case of this trap — a cancer PCR diagnosis — on Substack last week: https://rkoch.substack.com/p/when-pcr-becomes-a-cancer-diagnosis

[IMA-HelenT]

Thank you @RobertKoch … Great substack, it had me at the opening line “I get a dull, painful feeling every time someone tells me a friend or a relative has been diagnosed with cancer” … I have two friends undergoing aggressive chemo for breast cancer and one thing I did not think to ask was about the type of biopsy they had.

I really do worry about the amount of overdiagnosis that could be taking place. I need to spend some more time reading your substack, but I will share it with the team as I am sure they will be interested.

[RobertKoch]

Helen — thank you, and I’m sorry to hear about your friends. The biopsy-type question is exactly the right one to be asking now, because the answer determines what they’re actually being treated for.

Two distinctions worth knowing:

Tissue biopsy vs. liquid biopsy. A tissue biopsy (core needle, surgical excision) examines actual cells under a microscope and reads their architecture — what pathologists have done since the 19th century. A liquid biopsy (blood draw, “circulating tumor DNA,” Grail-style screens) doesn’t look at any cells at all. It runs PCR or sequencing on fragments in blood and infers cancer from amplified signal. Same word, different worlds.

Morphology vs. molecular markers. Even within tissue biopsy, ask whether the diagnosis was driven by cellular morphology (what the cells look like to a pathologist) or by molecular markers — IHC stains, FISH, PCR panels. The morphological diagnosis is the one with a century of mortality data behind it. The molecular markers are useful for sub-classification but were never validated as standalone diagnostic triggers, even though they are increasingly used that way.

But here is the harder point, and the one most people miss: without access to the complete medical record, it is impossible to tell whether your friends were actually diagnosed or whether the test result was used to convince them they were sick and required intervention. Those are not the same event, and the difference is invisible from the outside.

I saw this in my own investigative work. Of the 50+ criminal HIV prosecutions I investigated as a forensic investigator, in every single case the defendant’s “diagnosis” rested entirely on what the test had told the doctor. None of them — not one — had been diagnosed in any independent clinical sense. The test produced a label; the label produced a treatment plan; the treatment plan produced the record. The original question — is this person actually sick? — was never asked.

I am documenting all of this in detail in my forthcoming book.

Please share whatever’s useful with the team. And whatever you do, keep asking the question you just asked — that instinct is the one that saves people.

— Robert